Literature DB >> 28951327

Circulating B cells in type 1 diabetics exhibit fewer maturation-associated phenotypes.

Patrick Hanley1, Jennifer A Sutter2, Noah G Goodman3, Yangzhu Du4, Debora R Sekiguchi5, Wenzhao Meng4, Michael R Rickels6, Ali Naji7, Eline T Luning Prak8.   

Abstract

Although autoantibodies have been used for decades as diagnostic and prognostic markers in type 1 diabetes (T1D), further analysis of developmental abnormalities in B cells could reveal tolerance checkpoint defects that could improve individualized therapy. To evaluate B cell developmental progression in T1D, immunophenotyping was used to classify circulating B cells into transitional, mature naïve, mature activated, and resting memory subsets. Then each subset was analyzed for the expression of additional maturation-associated markers. While the frequencies of B cell subsets did not differ significantly between patients and controls, some T1D subjects exhibited reduced proportions of B cells that expressed transmembrane activator and CAML interactor (TACI) and Fas receptor (FasR). Furthermore, some T1D subjects had B cell subsets with lower frequencies of class switching. These results suggest circulating B cells exhibit variable maturation phenotypes in T1D. These phenotypic variations may correlate with differences in B cell selection in individual T1D patients.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  B lymphocytes; FasR; TACI; Type 1 diabetes

Mesh:

Year:  2017        PMID: 28951327      PMCID: PMC5673557          DOI: 10.1016/j.clim.2017.09.021

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  77 in total

1.  Circulating lymphocyte subsets in normal adults are variable and can be clustered into subgroups.

Authors:  Debora R Sekiguchi; Sara B Smith; Jennifer A Sutter; Noah G Goodman; Kathleen Propert; Yoram Louzoun; Wade Rogers; Eline T Luning Prak
Journal:  Cytometry B Clin Cytom       Date:  2011-04-06       Impact factor: 3.058

2.  TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease.

Authors:  J A Gross; J Johnston; S Mudri; R Enselman; S R Dillon; K Madden; W Xu; J Parrish-Novak; D Foster; C Lofton-Day; M Moore; A Littau; A Grossman; H Haugen; K Foley; H Blumberg; K Harrison; W Kindsvogel; C H Clegg
Journal:  Nature       Date:  2000-04-27       Impact factor: 49.962

3.  Identification and characterization of circulating human transitional B cells.

Authors:  Gary P Sims; Rachel Ettinger; Yuko Shirota; Cheryl H Yarboro; Gabor G Illei; Peter E Lipsky
Journal:  Blood       Date:  2005-02-08       Impact factor: 22.113

Review 4.  Immunologic and metabolic biomarkers of β-cell destruction in the diagnosis of type 1 diabetes.

Authors:  Jasmin Lebastchi; Kevan C Herold
Journal:  Cold Spring Harb Perspect Med       Date:  2012-06       Impact factor: 6.915

Review 5.  Autoimmune lymphoproliferative syndrome: molecular basis of disease and clinical phenotype.

Authors:  Austen Worth; Adrian J Thrasher; H Bobby Gaspar
Journal:  Br J Haematol       Date:  2006-04       Impact factor: 6.998

6.  CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation.

Authors:  Fabian Flores-Borja; Anneleen Bosma; Dorothy Ng; Venkat Reddy; Michael R Ehrenstein; David A Isenberg; Claudia Mauri
Journal:  Sci Transl Med       Date:  2013-02-20       Impact factor: 17.956

7.  CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients.

Authors:  Paul A Blair; Lina Yassin Noreña; Fabian Flores-Borja; David J Rawlings; David A Isenberg; Michael R Ehrenstein; Claudia Mauri
Journal:  Immunity       Date:  2010-01-14       Impact factor: 31.745

Review 8.  Islet Autoantibodies.

Authors:  Vito Lampasona; Daniela Liberati
Journal:  Curr Diab Rep       Date:  2016-06       Impact factor: 4.810

9.  B-lymphocyte depletion with rituximab and β-cell function: two-year results.

Authors:  Mark D Pescovitz; Carla J Greenbaum; Brian Bundy; Dorothy J Becker; Stephen E Gitelman; Robin Goland; Peter A Gottlieb; Jennifer B Marks; Antoinette Moran; Philip Raskin; Henry Rodriguez; Desmond A Schatz; Diane K Wherrett; Darrell M Wilson; Jeffrey P Krischer; Jay S Skyler
Journal:  Diabetes Care       Date:  2013-09-11       Impact factor: 19.112

10.  Multi-parametric flow cytometric and genetic investigation of the peripheral B cell compartment in human type 1 diabetes.

Authors:  W S Thompson; M L Pekalski; H Z Simons; D J Smyth; X Castro-Dopico; H Guo; C Guy; D B Dunger; S Arif; M Peakman; C Wallace; L S Wicker; J A Todd; R C Ferreira
Journal:  Clin Exp Immunol       Date:  2014-09       Impact factor: 4.330

View more
  15 in total

1.  A study of 51 subtypes of peripheral blood immune cells in newly diagnosed young type 1 diabetes patients.

Authors:  A Oras; A Peet; T Giese; V Tillmann; R Uibo
Journal:  Clin Exp Immunol       Date:  2019-06-21       Impact factor: 4.330

2.  Protein-engineered molecules carrying GAD65 epitopes and targeting CD35 selectively down-modulate disease-associated human B lymphocytes.

Authors:  I K Manoylov; G V Boneva; I A Doytchinova; N M Mihaylova; A I Tchorbanov
Journal:  Clin Exp Immunol       Date:  2019-05-09       Impact factor: 4.330

3.  Effect of Cholecalciferol Supplementation on the Clinical Features and Inflammatory Markers in Hospitalized COVID-19 Patients: A Randomized, Open-Label, Single-Center Study.

Authors:  Tatiana L Karonova; Ksenia A Golovatyuk; Igor V Kudryavtsev; Alena T Chernikova; Arina A Mikhaylova; Arthur D Aquino; Daria I Lagutina; Ekaterina K Zaikova; Olga V Kalinina; Alexey S Golovkin; William B Grant; Evgeny V Shlyakhto
Journal:  Nutrients       Date:  2022-06-23       Impact factor: 6.706

4.  Loss of CXCR3 expression on memory B cells in individuals with long-standing type 1 diabetes.

Authors:  Wendy E Powell; Stephanie J Hanna; Claire N Hocter; Emma Robinson; Joanne Davies; Gareth J Dunseath; Stephen Luzio; Daniel Farewell; Li Wen; Colin M Dayan; David A Price; Kristin Ladell; F Susan Wong
Journal:  Diabetologia       Date:  2018-06-07       Impact factor: 10.122

5.  Impact of deranged B cell subsets distribution in the development of HCV-related cirrhosis and HCC in type two diabetes mellitus.

Authors:  Fadwa A Abdelwahab; Khaled M Hassanein; Helal F Hetta; Mohamed O Abdelmalek; Asmaa M Zahran; Omnia El-Badawy
Journal:  Sci Rep       Date:  2020-11-23       Impact factor: 4.379

Review 6.  B Quiet: Autoantigen-Specific Strategies to Silence Raucous B Lymphocytes and Halt Cross-Talk with T Cells in Type 1 Diabetes.

Authors:  Jamie L Felton; Holly Conway; Rachel H Bonami
Journal:  Biomedicines       Date:  2021-01-06

7.  Increased plasmablasts enhance T cell-mediated beta cell destruction and promote the development of type 1 diabetes.

Authors:  Qing Ling; Lei Shen; Wei Zhang; DuoDuo Qu; Hongdong Wang; Bin Wang; Yong Liu; Jing Lu; Dalong Zhu; Yan Bi
Journal:  Mol Med       Date:  2022-02-05       Impact factor: 6.354

Review 8.  The Multiple Roles of B Lymphocytes in the Onset and Treatment of Type 1 Diabetes: Interactions between B Lymphocytes and T Cells.

Authors:  Yangfan Xiao; Chao Deng; Zhiguang Zhou
Journal:  J Diabetes Res       Date:  2021-11-03       Impact factor: 4.011

9.  Slow progressors to type 1 diabetes lose islet autoantibodies over time, have few islet antigen-specific CD8+ T cells and exhibit a distinct CD95hi B cell phenotype.

Authors:  Stephanie J Hanna; Wendy E Powell; Anna E Long; Emma J S Robinson; Joanne Davies; Clare Megson; Alexandra Howell; Taz J Jones; Kristin Ladell; David A Price; Colin M Dayan; Alistair J K Williams; Kathleen M Gillespie; F Susan Wong
Journal:  Diabetologia       Date:  2020-03-10       Impact factor: 10.122

10.  Mass Cytometry Studies of Patients With Autoimmune Endocrine Diseases Reveal Distinct Disease-Specific Alterations in Immune Cell Subsets.

Authors:  Louise Magnusson; Hugo Barcenilla; Mikael Pihl; Sophie Bensing; Daniel Espes; Per-Ola Carlsson; Rosaura Casas
Journal:  Front Immunol       Date:  2020-02-21       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.